+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biopharmaceuticals Market By Type and Application - Global Opportunity Analysis And Industry Forecast, 2018-2025

  • ID: 4612776
  • Report
  • July 2018
  • Region: Global
  • 255 pages
  • Allied Analytics LLP
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen, Inc.
  • Bayer AG
  • Biogen, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • MORE
Biopharmaceuticals are drugs having a biological origin. These large and complex drugs, which often comprise heterogeneous mixtures, are produced using biotechnology and usually from genetically engineered cells. The global biopharmaceuticals market accounted for $186,470 million in 2017, and is projected to reach $526,008 million by 2025, registering a CAGR of 13.8% from 2018 to 2025.

The global biopharmaceuticals market is driven by various factors, such as surge in prevalence of chronic diseases and rapid increase in the elderly population globally. Similarly, increase in strategic collaboration among the biopharmaceuticals companies is also expected to boost the market. However, high costs of drug development and a stringent regulatory scenario with respect to biopharmaceuticals are anticipated to impede the market growth. Conversely, increase in purchasing power of emerging economics is anticipated to provide lucrative opportunities to the market players throughout the forecast period.

The global biopharmaceuticals market is segmented based on type, application, and region. Based on type, the market is divided into monoclonal antibody, interferon, insulin, growth and coagulation factor, erythropoietin, vaccine, hormone, and others. By application, it is categorized into oncology, blood disorder, metabolic disease, infectious disease, cardiovascular disease, neurological disease, immunology, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).

KEY MARKET BENEFITS

The study provides an in-depth analysis of the global biopharmaceuticals market along with the current trends and future estimations to elucidate the imminent investment pockets.
The report presents a quantitative analysis of the market from 2017 to 2025 to enable stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the market based on application assists in understanding the trends in the industry.
The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By product

Monoclonal antibody
Interferon
Insulin
Growth and coagulation factor
Erythropoietin
Vaccine
Hormone
Others

By application

Oncology
Blood disorder
Metabolic disease
Infectious disease
Cardiovascular disease
Neurological disease
Immunology
Others

By geography

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

The list of key players operating in this market includes:

Abbott Laboratories
Amgen, Inc.
Biogen, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche, Ltd.
Johnson & Johnson
Merck & Co., Inc.
Novo Nordisk A/S
Pfizer, Inc.
Sanofi

The OTHER PLAYERS included in the value chain analysis (and not included in the report) include:

Bristol Myers Squibb Company
Bayer AG
Shire plc
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen, Inc.
  • Bayer AG
  • Biogen, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • MORE
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Market Share Analysis, 2017
3.4. Clinical trials
3.5. Patent analysis, 2014-2018
3.5.1. Patent analysis, by year (2014-2018)
3.5.2. Patent analysis, by country
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in prevalence of chronic diseases
3.6.1.2. Rise in geriatric population and improvement in healthcare infrastructure
3.6.1.3. Increase in strategic acquisitions and collaborations
3.6.2. Restraints
3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Stringent regulatory scenario
3.6.3. Opportunity
3.6.3.1. Increase in purchasing power of emerging economics

CHAPTER 4: BIOPHARMACEUTICALS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Monoclonal Antibodies
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Interferons
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Insulin
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Growth and coagulation factors
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Erythropoietin
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Vaccines
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Hormones
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. Other
4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country

CHAPTER 5: BIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oncology
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Blood Disorders
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Metabolic Diseases
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Infectious Diseases
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Cardiovascular Diseases
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Neurological Diseases
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
5.8. Immunology
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country
5.9. Other Applications
5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by country

CHAPTER 6: BIOPHARMACEUTICALS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America Biopharmaceuticals market size and forecast, by country
6.2.2.1. U.S. market size and forecast
6.2.2.1.1. U.S. Biopharmaceuticals market, by type
6.2.2.1.2. U.S. Biopharmaceuticals market, by application
6.2.2.2. Canada market size and forecast
6.2.2.2.1. Canada Biopharmaceuticals market, by type
6.2.2.2.2. Canada Biopharmaceuticals market, by application
6.2.2.3. Mexico market size and forecast
6.2.2.3.1. Mexico Biopharmaceuticals market, by type
6.2.2.3.2. Mexico Biopharmaceuticals market, by application
6.2.3. North America Biopharmaceuticals market size and forecast, by type
6.2.4. North America Biopharmaceuticals market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe Biopharmaceuticals market size and forecast, by country
6.3.2.1. Germany market size and forecast
6.3.2.1.1. Germany. Biopharmaceuticals market, by type
6.3.2.1.2. Germany Biopharmaceuticals market, by application
6.3.2.2. France market size and forecast
6.3.2.2.1. France Biopharmaceuticals market, by type
6.3.2.2.2. France Biopharmaceuticals market, by application
6.3.2.3. UK market size and forecast
6.3.2.3.1. UK Biopharmaceuticals market, by type
6.3.2.3.2. UK Biopharmaceuticals market, by application
6.3.2.4. Italy market size and forecast
6.3.2.4.1. Italy Biopharmaceuticals market, by type
6.3.2.4.2. Italy Biopharmaceuticals market, by application
6.3.2.5. Spain market size and forecast
6.3.2.5.1. Spain. Biopharmaceuticals market, by type
6.3.2.5.2. Spain Biopharmaceuticals market, by application
6.3.2.6. Rest of Europe market size and forecast
6.3.2.6.1. Rest of Europe Biopharmaceuticals market, by type
6.3.2.6.2. Rest of Europe Biopharmaceuticals market, by application
6.3.3. Europe Biopharmaceuticals market size and forecast, by type
6.3.4. Europe Biopharmaceuticals market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific Biopharmaceuticals market size and forecast, by country
6.4.2.1. Japan market size and forecast
6.4.2.1.1. Japan Biopharmaceuticals market, by type
6.4.2.1.2. Japan Biopharmaceuticals market, by application
6.4.2.2. China market size and forecast
6.4.2.2.1. China Biopharmaceuticals market, by type
6.4.2.2.2. China Biopharmaceuticals market, by application
6.4.2.3. India market size and forecast
6.4.2.3.1. India Biopharmaceuticals market, by type
6.4.2.3.2. India Biopharmaceuticals market, by application
6.4.2.4. Australia market size and forecast
6.4.2.4.1. Australia Biopharmaceuticals market, by type
6.4.2.4.2. Australia Biopharmaceuticals market, by application
6.4.2.5. South Korea market size and forecast
6.4.2.5.1. South Korea Biopharmaceuticals market, by type
6.4.2.5.2. South Korea Biopharmaceuticals market, by application
6.4.2.6. Rest of Asia-Pacific market size and forecast
6.4.2.6.1. Rest of Asia-Pacific Biopharmaceuticals market, by type
6.4.2.6.2. Rest of Asia-Pacific Biopharmaceuticals market, by application
6.4.3. Asia-Pacific Biopharmaceuticals market size and forecast, by type
6.4.4. Asia-Pacific Biopharmaceuticals market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA Biopharmaceuticals market size and forecast, by country
6.5.2.1. Brazil market size and forecast
6.5.2.1.1. Brazil Biopharmaceuticals market, by type
6.5.2.1.2. Brazil Biopharmaceuticals market, by application
6.5.2.2. Saudi Arabia market size and forecast
6.5.2.2.1. Saudi Arabia. Biopharmaceuticals market, by type
6.5.2.2.2. Saudi Arabia Biopharmaceuticals market, by application
6.5.2.3. South Africa market size and forecast
6.5.2.3.1. South Africa Biopharmaceuticals market, by type
6.5.2.3.2. South Africa Biopharmaceuticals market, by application
6.5.2.4. Rest of LAMEA market size and forecast
6.5.2.4.1. Rest of LAMEA Biopharmaceuticals market, by type
6.5.2.4.2. Rest of LAMEA Biopharmaceuticals market, by application
6.5.3. LAMEA Biopharmaceuticals market size and forecast, by type
6.5.4. LAMEA Biopharmaceuticals market size and forecast, by application

CHAPTER 7: COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. Amgen Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Biogen Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Eli Lilly and Company
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. F. Hoffmann-La Roche Ltd.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Johnson & Johnson
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Merck & Co., Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Novo Nordisk A/S
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Pfizer Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Sanofi
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen, Inc.
  • Bayer AG
  • Biogen, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • MORE
According to a new report, titled, Biopharmaceuticals Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2018-2025, the market was valued at $186,470 million in 2017, and is projected to reach $526,008 million by 2025, growing at a CAGR of 13.8% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.

Biopharmaceuticals, also known as biologics, are drugs that are manufactured in living systems, such as microorganisms and animal cells. An array of different biopharmaceuticals is also produced using recombint D technology. The biopharmaceuticals sector is the fastest-growing segment of the pharmaceutical industry.

The global biopharmaceuticals market is anticipated to grow considerably in the near future, owing to various factors, such as strategic collaborations among biopharmaceuticals companies, increase in obesity and sedentary lifestyle among the population, rise in elderly population, and upsurge in prevalence of chronic diseases, such as cancer, globally. However, high costs associated with biopharmaceuticals drug development and a stringent regulatory scerio are key factors expected to impede the market growth. On the contrary, emerging markets, such as India and Chi, are anticipated to provide lucrative growth opportunities to the market players during the forecast period.

By type, the monoclol antibody segment accounted for nearly two-fifths share of the global biopharmaceuticals market in 2017. In terms of application, the oncology segment accounted for one-third share in 2017, and is projected to exhibit a prominent growth rate, owing to surge in cancer prevalence globally. By region, North America generated the highest revenue in the global biopharmaceuticals market in 2017.

Key Findings of the Biopharmaceuticals Market:

The monoclol antibody segment is anticipated to domite the global biopharmaceuticals market from 2018 to 2025.
The metabolic disease application is anticipated to grow with the highest CAGR throughout the forecast period.
North America accounted for a share of more than two-fifths of the global biopharmaceuticals market in 2017.
The Asia-Pacific region is anticipated to grow at the highest rate in the global biopharmaceuticals market during the forecast period, followed by LAMEA.

North America held the highest market share in 2017, owing to high prevalence rate of cancer and other chronic diseases, adoption of biologics, and increase in awareness about biopharmaceuticals. The Asia-Pacific region is expected to grow at the highest CAGR of 17.2% during the forecast period, owing to rapid industrialization in the area, increase in disposable income, and upsurge in government initiatives to modernize the healthcare infrastructure.

The report provides an extensive competitive Analysis and profiles of the key market players, such as Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer, Inc., and Sanofi. The other players in the value chain (not included in the report) include Bristol Myers Squibb Company, Bayer AG, and Shire plc.
Note: Product cover images may vary from those shown
5 of 5
  • Abbott Laboratories
  • Amgen, Inc.
  • Biogen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche, Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Sanofi
  • Bristol Myers Squibb Company
  • Bayer AG
  • Shire plc
Note: Product cover images may vary from those shown
6 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll